This study will determine how certain features of depressed individuals affect their
responses to depression treatment.
Major depression is a serious condition that can have devastating functional consequences.
Although numerous depression studies have been conducted, understanding of how best to
achieve long-term recovery remains limited. This study will assess the mood, personality,
pharamcokinetic and genetic characteristics of depressed participants to determine the
effects of these features on treatment response.
This study will be conducted at two international treatment sites, including the University
of Pittsburgh and the University of Pisa, Italy. Participants will be randomly assigned to
receive either interpersonal psychotherapy (IPT) or escitalopram pharmacotherapy for a
minimum of 32 weeks or approximately 8 months. Participants whose symptoms become stabilized
will continue the initial treatment for another 6 months; those who do not will have the
second treatment added to their regimen until remission occurs. Clinical evaluations and
questionnaires will be used to assess participants.
- Diagnosis of Major depression
- History of manic or hypomanic episodes
- History of schizophrenia or schizoaffective disorder
- Diagnosis of anorexia nervosa or bulimia nervosa
- Current psychosis
- Drug and/or alcohol dependence or abuse within 3 months prior to study entry.
Participants with episodic abuse related to mood disorders will not be excluded.
- Diagnosis of antisocial personality disorder
- Diagnosis of organic affective syndrome and uncontrolled medical illness
- Require inpatient treatment for suicidal risk or psychosis
- History of an inability to tolerate any of the study treatments
- Currently receiving treatment with an effective antidepressant